Clinical Trial Update: A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating AMG 334 Injection for preventing episodic migraines in adults after failure of other therapies has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Episodic Migraine

Drugs mentioned

• AMG 334 Injection

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Episodic Migraine | Phase 3 | Status: COMPLETED | Results posted: 2022-02-18